At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APLS Apellis Pharmaceuticals Inc.
Pre-Market Trading 05-10 05:12:19 EDT
42.52
+0.22
+0.52%
High43.00
Low41.71
Vol1.06M
Open42.73
D1 Closing42.30
Amplitude3.05%
Mkt Cap5.16B
Tradable Cap3.48B
Total Shares121.37M
T/O44.94M
T/O Rate1.30%
Tradable Shares81.88M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.